Was the 10x Genomics (TXG) CEO’s share sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the transaction was executed under Serge Saxonov’s Rule 10b5-1 trading plan adopted on November 29, 2025. Such plans pre-schedule trades, indicating the timing of this 5,000-share sale was arranged in advance rather than decided spontaneously.

10x Genomics (NASDAQ: TXG) CEO sells 5,000 shares in 10b5-1 trade

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

10x Genomics, Inc. Chief Executive Officer Serge Saxonov sold 5,000 shares of Class A Common Stock in an open-market transaction at a weighted average price of $24.5568 per share on April 14, 2026. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2025, indicating it was scheduled in advance.

Following the sale, Saxonov directly holds 1,167,273 shares of Class A Common Stock. He also has indirect holdings through trusts where he serves as trustee, including 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 71,644 shares in the Y/S Pot Trust.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares ($122,784)

Net Sell 4 txns

Insider Saxonov Serge

Role Chief Executive Officer

Sold 5,000 shs ($123K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	5,000	$24.5568	$123K
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 1,167,273 shares (Direct); Class A Common Stock — 27 shares (Indirect, See footnote)

Footnotes (1)

The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. This transaction was executed in multiple trades at prices ranging from $24.49 to $24.70, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

Key Figures

Shares sold: 5,000 shares Weighted average sale price: $24.5568 per share Sale price range: $24.49–$24.70 per share +5 more

8 metrics

Shares sold 5,000 shares Open-market sale on April 14, 2026

Weighted average sale price $24.5568 per share Class A Common Stock sale

Sale price range $24.49–$24.70 per share Multiple trades within stated range

Direct holdings after transaction 1,167,273 shares Class A Common Stock held directly by CEO

Andromeda Trust holdings 27 shares Indirect holding; CEO serves as trustee

Y/S Descendants' Trust holdings 213,250 shares Indirect holding; CEO serves as trustee

Y/S Pot Trust holdings 71,644 shares Indirect holding; CEO serves as trustee

Rule 10b5-1 plan adoption date November 29, 2025 Governs timing of the 5,000-share sale

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Class A Common Stock, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

Class A Common Stock financial

"security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

trustee financial

"for which the Reporting Person serves as trustee"

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

Form 4 Insider Transactions: What Each Field Means →

04/16/2026 - 04:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saxonov Serge

(Last)

(First)

(Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON

CALIFORNIA

94588

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	04/14/2026		S⁽¹⁾		5,000	D	$24.5568⁽²⁾	1,167,273	D
Class A Common Stock								27	I	See footnote⁽³⁾
Class A Common Stock								213,250	I	See footnote⁽⁴⁾
Class A Common Stock								71,644	I	See footnote⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

2. This transaction was executed in multiple trades at prices ranging from $24.49 to $24.70, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

4. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

5. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

	/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did 10x Genomics (TXG) CEO Serge Saxonov report in this Form 4?

Serge Saxonov reported selling 5,000 shares of 10x Genomics Class A Common Stock at a weighted average price of $24.5568 on April 14, 2026. The filing also updates his remaining direct and trust-held share positions after the transaction.

How many 10x Genomics (TXG) shares did the CEO sell and at what price?

The CEO sold 5,000 shares of 10x Genomics Class A Common Stock in an open-market transaction. The weighted average sale price was $24.5568 per share, with individual trade prices ranging from $24.49 to $24.70, as detailed in the Form 4 footnotes.

How many 10x Genomics (TXG) shares does the CEO hold after this sale?

After the sale, the CEO directly holds 1,167,273 shares of Class A Common Stock. He also has indirect holdings via trusts where he serves as trustee, including 27 shares in the Andromeda Trust, 213,250 in the Y/S Descendants' Trust, and 71,644 in the Y/S Pot Trust.

What indirect 10x Genomics (TXG) holdings are disclosed for the CEO?

The filing lists three trust positions: 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 71,644 shares in the Y/S Pot Trust. In each case, Serge Saxonov is identified as trustee, indicating he has authority over these trust-held shares.

How is the sale price range for the 10x Genomics (TXG) CEO’s trade described?

The Form 4 notes the 5,000-share transaction occurred in multiple trades between $24.49 and $24.70 per share. The reported $24.5568 figure is a weighted average, and the CEO undertakes to provide detailed trade breakdowns upon request to regulators, the issuer, or security holders.